Abstract
Introduction: Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). SPRMs are a new class of progesterone-receptor ligands that exert tissue selective agonist, antagonist or mixed agonist-antagonist activity in target cells. UPA inhibits the proliferation, induces apoptosis of leiomyoma cells in vitro and demonstrates potent progesterone antagonist activity in vitro and in vivo.Areas covered: This manuscript aims to review the available data on safety of UPA in the treatment of uterine fibroids. Data and articles included in this manuscript were obtained via PubMed, Medline and Embase up to November 2014.Expert opinion: UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life. Short-term administration of UPA has been shown to be safe at short follow-up (months) and it is associated with minimal adverse side effects; further studies with longer follow-up are required to define the safety profile of UPA on endometrial histology.
| Original language | English |
|---|---|
| Pages (from-to) | 965-977 |
| Number of pages | 13 |
| Journal | Expert Opinion on Drug Safety |
| Volume | 14 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2015 |
Fingerprint
Keywords
- Safety
- Selective progesterone-receptor modulators
- Tolerability
- Treatment
- Ulipristal acetate
- Uterine fibroids
ASJC Scopus subject areas
- Pharmacology (medical)
- Medicine(all)
Cite this
Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. / Tafi, Emanuela; Scala, Carolina; Maggiore, Umberto Leone Roberti; Bizzarri, Nicolò; Candiani, Massimo; Venturini, Pier Luigi; Ferrero, Simone.
In: Expert Opinion on Drug Safety, Vol. 14, No. 6, 01.06.2015, p. 965-977.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids
AU - Tafi, Emanuela
AU - Scala, Carolina
AU - Maggiore, Umberto Leone Roberti
AU - Bizzarri, Nicolò
AU - Candiani, Massimo
AU - Venturini, Pier Luigi
AU - Ferrero, Simone
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Introduction: Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). SPRMs are a new class of progesterone-receptor ligands that exert tissue selective agonist, antagonist or mixed agonist-antagonist activity in target cells. UPA inhibits the proliferation, induces apoptosis of leiomyoma cells in vitro and demonstrates potent progesterone antagonist activity in vitro and in vivo.Areas covered: This manuscript aims to review the available data on safety of UPA in the treatment of uterine fibroids. Data and articles included in this manuscript were obtained via PubMed, Medline and Embase up to November 2014.Expert opinion: UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life. Short-term administration of UPA has been shown to be safe at short follow-up (months) and it is associated with minimal adverse side effects; further studies with longer follow-up are required to define the safety profile of UPA on endometrial histology.
AB - Introduction: Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). SPRMs are a new class of progesterone-receptor ligands that exert tissue selective agonist, antagonist or mixed agonist-antagonist activity in target cells. UPA inhibits the proliferation, induces apoptosis of leiomyoma cells in vitro and demonstrates potent progesterone antagonist activity in vitro and in vivo.Areas covered: This manuscript aims to review the available data on safety of UPA in the treatment of uterine fibroids. Data and articles included in this manuscript were obtained via PubMed, Medline and Embase up to November 2014.Expert opinion: UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life. Short-term administration of UPA has been shown to be safe at short follow-up (months) and it is associated with minimal adverse side effects; further studies with longer follow-up are required to define the safety profile of UPA on endometrial histology.
KW - Safety
KW - Selective progesterone-receptor modulators
KW - Tolerability
KW - Treatment
KW - Ulipristal acetate
KW - Uterine fibroids
UR - http://www.scopus.com/inward/record.url?scp=84929577580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929577580&partnerID=8YFLogxK
U2 - 10.1517/14740338.2015.1021773
DO - 10.1517/14740338.2015.1021773
M3 - Article
C2 - 25772793
AN - SCOPUS:84929577580
VL - 14
SP - 965
EP - 977
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 6
ER -